- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01468376
GLU-xx Formulations in Individuals With Impaired Glucose Tolerance
An Open-label, Dose-finding Pilot Study of Various Formulations of Glucose-lowering Products in Otherwise Healthy Individuals With Impaired Glucose Tolerance
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Northridge, California, United States, 91325
- Staywell Research LLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Generally healthy adults between 21-65 years of age
- Body Mass Index (BMI) between 25 and ≤40
- OGTT (75g glucola) peak value between ≥140mg/dl and ≤199 mg/dl at screening visit
- Willingness to adhere to the requirements of the protocol, including availability for follow-up visits and donation of blood samples
- Willingness and ability to sign written informed consent
- Women of child bearing capacity who agree to use an acceptable form of birth control during the trial [i.e., oral contraception, reliable use of a double-barrier method (e.g., condom and diaphragm, condom and foam, condom and sponge), IUD or tubal ligation]
Exclusion Criteria:
- Active diabetes mellitus [fasting blood glucose of ≥7.0 mmol/L (≥126 mg/dL) or ≥11.1 mmol/L (≥200 mg/dL) after OGTT]
- Current coronary artery/ cardiovascular disease or history of a cardiovascular event (stroke, transient ischemic attack, myocardial infarction, angioplasty or coronary artery bypass grafting, angina pectoris) or have undergone a cardiovascular intervention within the past three months
- Seizure disorder
- Blood disorders, including anemia (i.e., hemoglobin levels less than 13 g/dL in men and less than 12 g/dL in women)
- Active infection, including HIV, hepatitis, etc
- Participants on Estrogen replacement must be on a stable dose for at least 3 months
- Serious illness requiring ongoing medical care or medication
- Gastrointestinal disorders or prior gastrointestinal surgeries (including gastric bypass or lap-band) that might cause complications or influence motility or satiety (e.g.,diverticulitis, inflammatory bowel disease, irritable bowel syndrome, intestinal narrowing or obstruction, difficulty swallowing)
- Any congenital spinal cord deformities or traumatic spinal cord injuries
- Uncorrected hypothyroidism
- Other significant metabolic endocrine disease
- Active liver disease or liver function impairment as evidenced by a history of liver disease or liver enzyme elevations >three times the upper limit of normal
- Current cancer
- Significant kidney disease (calculated by eGFR <60 mL/min)
- History or clinical manifestations of significant metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological,or psychiatric disorders which in the opinion of the investigator would be expected to interfere with the study or increase risk to the subject
- Use of anticoagulants such as warfarin
- Use of medications that might affect weight or food absorption (e.g., diuretics,glucocorticoids, anorexigenic agents, Orlistat, laxatives)
- Treatment within the previous 6 months with any medication that is known to affect glucose levels (such as insulin with or without an amylin analogue, sulfonylureas,meglitinides, biguanide metformin, thiazolidinediones, alpha-glucosidase inhibitors,oral dipeptidyl-peptidase-4 inhibitor, Sitagliptin, Incretin mimetic)
Regular use of natural health products or dietary supplements known to affect glucose levels (such as chromium, zinc, fenugreek, cinnamon). If the participant agrees to stop taking these products 14 days prior to study entry and for the duration of the study, they can participate in the study
o Any other natural health products or dietary supplements, with the exception of vitamins and minerals with dose of < 600 mg/day of vitamin E and containing no vitamin K. Natural health products or dietary supplements include products such as, but not limited to, Echinacea, Ginseng, St. John's Wort, Gingko, Glucosamine, Fish Oil supplements, Evening Primrose Oil, Green Tea or other herbal products consumed in the form of pills, extracts, capsules, or tablets. If the participant agrees to stop taking these products 14 days prior to study entry and for the duration of the study, they can participate in the study
- Vegan or Vegetarian
- Pregnant or lactating women, or intending to become pregnant
- Known allergy to any ingredient in the study product
- Any significant auto-immune disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GLU-01
|
14 day dosing
|
Experimental: GLU-02
|
14 day dosing
|
Experimental: GLU-03
|
14 day dosing
|
Experimental: GLU-04
|
14 day dosing
|
Experimental: GLU-05
|
14 day dosing
|
Experimental: GLU-06
|
14 day dosing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Glucose and insulin response to the Oral Glucose Tolerance Test after administration of GLU-xx formulations
Time Frame: 14 days
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability of GLU-xx formulations
Time Frame: 14 Days
|
14 Days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jay Udani, MD, Medicus Research LLC/Staywell Research LLC
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GLU-00-2010-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Impaired Glucose Tolerance
-
Psychiatric Centre RigshospitaletUniversity of Cambridge; University Hospital, Gentofte, CopenhagenUnknownImpaired Glucose Tolerance Associated With DrugsDenmark
-
Columbia UniversityCompletedBody Weight | Impaired Glucose Tolerance in ObeseUnited States
-
Maastricht University Medical CenterCompletedObesity | Insulin Resistance | Impaired Glucose Tolerance in ObeseNetherlands
-
The University of Texas Health Science Center at...Amylin Pharmaceuticals, LLC.CompletedDiabetes | Impaired Glucose Tolerance (IGT)United States
-
Wroclaw Medical UniversityCompletedPreDiabetes | Impaired Glucose Tolerance (IGT) | Impaired Fasting Glucose (IFG)Poland
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedT2D | IGT - Impaired Glucose ToleranceUnited States
-
The University of Texas Health Science Center at...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); A... and other collaboratorsRecruitingDiabetes Mellitus, Type 2 | Impaired Glucose Tolerance (IGT) | Impaired Fasting Glucose (IFG)United States
-
University of Oslo School of PharmacyCompletedRenal Transplant Recipients | Posttransplant Diabetes Mellitus | Posttransplant Impaired Glucose ToleranceNorway
-
University of OsloCompleted
Clinical Trials on GLU-01
-
University of IowaCompletedHyperglycemia | Endothelial FunctionUnited States
-
University Hospital Inselspital, BerneUniversity of Lausanne; University of BernCompletedHypoglycemia | Exercise | Type 1 Diabetes Mellitus | Carbohydrate MetabolismSwitzerland
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not yet recruitingType 1 DiabetesUnited States
-
Livzon Pharmaceutical Group Inc.Active, not recruiting
-
Ixchelsis LimitedCompletedPremature EjaculationUnited States
-
Zucara Therapeutics Inc.RecruitingType 1 Diabetes Mellitus With HypoglycemiaUnited States, Canada
-
Maastricht University Medical CenterCompletedType 2 Diabetes MellitusNetherlands
-
Shanghai Hongyitang Biopharmaceutical Technology...Completed
-
Enterin Inc.TerminatedParkinson Disease | ConstipationUnited States
-
Zhongmou TherapeuticsRecruitingX-linked RetinoschisisChina